#BioA

BioAge Announces Proposed Public Offering BioAge (Nasdaq: BIOA) on January 20, 2026 announced a proposed underwritten public offering of up to $75.0 million of common stock, with a 30-day underwriter option to purchase up to an additional $11.25 million. All shares will be offered by the company and the offering is subject to market and other conditions with no assurance of completion or final terms. Goldman Sachs, Piper Sandler and Citigroup are joint book‑running managers. Net proceeds, together with existing cash and marketable securities, are intended to fund research, clinical and process development including BGE-102, NLRP3 and APJ programs, working capital, capex and reduction of indebtedness. The offering will be filed on Form S-3.

1 month ago

#BIOA BioAge Announces Proposed Public Offering

www.stocktitan.net/news/BIOA/bio-age-announ...

0 0 0 0

1 month ago

Just In: ( NASDAQ: #BIOA ) BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026

0 0 0 0

2 months ago

News; ( NASDAQ: #BIOA ) BioAge Announces Additional Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential for Best-in-Class hsCRP Reduction in Participants with Elevated Cardiovascular Risk

0 0 0 0

3 months ago

NEWS: ( NASDAQ: #BIOA ) 2 Reasons I Wouldn't Touch BioAge Labs Stock With a 10-Foot Pole

0 0 0 0

@smcapstrategist.bsky.social

3 months ago

News; ( NASDAQ: #BIOA ) BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor

0 0 0 0

Small Cap Strategist

3 months ago

Leading Indicators, Thursday December 4, 2025 – Crystal Equity Research

Small-cap stocks with strong volume gains, Thu Dec 4th - #PMI #WRAP #WNW #SNCR #QCLS #PLBY #MNY #KALA #ILLR #GNPX #DXLG #BIOA #AXGN - More: crystalequityresearch.com/leading-indi... - #smallcap

0 0 0 0

New Leqembi-data presented at CTAD 2025 suggests potential to delay disease progression by up to 8.3 years with continued treatment STOCKHOLM, Dec. 4, 2025/ PRNewswire/-- BioArctic AB's partner Eisai presented the latest findings on time saved with continued treatment with lecanemab at the 18 th Clinical Trials in Alzheimer's Disease conference, held in San Diego December 1-4. Data suggests potential to delay disease progression from Mild cognitive impairment to moderate Alzheimer's...

3 months ago

#B #BIOA New Leqembi-data presented at CTAD 2025 suggests potential to delay disease progression by up to 8.3 years with continued treatment

www.stocktitan.net/news/B/new-leqembi-data-...

0 0 0 0

3 months ago

News; ( NASDAQ: #BIOA ) BioAge Labs to Present at Piper Sandler 37th Annual Healthcare Conference

0 0 0 0

New data on lecanemab to be presented at CTAD conference BioArctic (Nasdaq: B) announced that partner Eisai will present new data on lecanemab (Leqembi) at the CTAD conference in San Diego, Dec 1–4, 2025.Presentations cover long‑term treatment analyses, estimated time savings over 10 years, safety and pharmacokinetics for a subcutaneous initiation option, effects on soluble Aβ protofibrils, and real‑world registry findings including ALZ‑NET and a Japanese post‑marketing study.

3 months ago

#B #BIOA #BIOAB New data on lecanemab to be presented at CTAD conference

www.stocktitan.net/news/B/new-data-on-lecan...

0 0 0 0

Leqembi® approved for IV maintenance treatment in the United Kingdom STOCKHOLM, Nov. 13, 2025/ PRNewswire/-- BioArctic AB's partner Eisai announced today that Leqembi has been approved for once every four weeks intravenous maintenance dosing for the treatment of early Alzheimer's disease by the Medicines and Healthcare products Regulatory Agency in the United Kingdom.. In August 2024, Leqembi was approved for the treatment of...

4 months ago

#B #BIOA Leqembi® approved for IV maintenance treatment in the United Kingdom

www.stocktitan.net/news/B/leqembi-approved-...

0 0 0 0

BioAge Labs Reports Third Quarter 2025 Financial Results and Provides Business Updates BioAge Labs,

4 months ago

#BIOA BioAge Labs Reports Third Quarter 2025 Financial Results and Provides Business Updates

www.stocktitan.net/news/BIOA/bio-age-labs-r...

0 0 0 0

Nasdaq

@nasdaq.activitypub.awakari.com.ap.brid.gy

4 months ago

#BIOA #9ed62868-6822-47aa-8f6c-5c34f67f5a16 #investing

Origin | Interest | Match

0 0 0 0

Health Canada Grants Authorization for Leqembi® (lecanemab) LEQEMBI is the first treatment for early AD that targets an underlying cause of the disease, to be authorized in Canada.. Leqembi is approved in 51 countries and regions including Japan, the United States, Europe, China, South Korea, Taiwan, and Saudi Arabia, and applications have been filed in 9 countries. In the Clarity AD study, Leqembi met its primary endpoint and...

4 months ago

#B #BIOA Health Canada Grants Authorization for Leqembi® (lecanemab)

www.stocktitan.net/news/B/health-canada-gra...

0 0 0 0

Citigroup upgrades rating, TP on obesity drugmaker BioAge amid upcoming clinical data – Oninvest Citigroup has upgraded to "buy" shares of small-cap obesity drug developer BioAge Labs, calling the company’s lead molecule promising, with the first-in-human study recently announced . The upgrade se...

4 months ago

Just In: ( NASDAQ: #BIOA ) BioAge Labs Stock Just Soared. Does It Have More Fuel to Climb Higher?

0 0 0 0

Oninvest

@oninvest.bsky.social

4 months ago

Citigroup upgraded #BIOA to Buy from Hold and raised its target to $10, citing strong potential for its obesity drug BGE-102, an NLRP3 inhibitor now in early human trials, details: en.oninvest.com/article/citi...

0 0 0 0

Sierra de las Nieves MM

@sierranievesmm.bsky.social

4 months ago

💚 Málaga apuesta por la custodia del territorio y la bioeconomía local.
📅 29/10 | 🕙 10–14h | 📍 #SierradelasNieves
Jornada con ponencias, networking y taller para impulsar proyectos sostenibles 🌿
#BioA #Sostenibilidad #CustodiaDelTerritorio #MálagaVerde

0 0 0 0

HitGen Partner BioAge Labs Initiates Phase 1 Clinical Study of BGE-102, a Novel Brain-Penetrant NLRP3 inhibitor BioAge Labs (NASDAQ:BIOA) has initiated a Phase 1 clinical study of BGE-102, a novel brain-penetrant NLRP3 inhibitor developed in collaboration with HitGen (SSE:688222). The drug candidate, discovered using HitGen's DNA-encoded library (DEL) technology platform, is being developed initially for obesity treatment.BGE-102 is an orally available small molecule that targets NLRP3, a key driver of age-related inflammation implicated in neurodegenerative conditions, cardiovascular disease, and metabolic disorders. The clinical trial initiation triggers an undisclosed milestone payment to HitGen under their collaboration agreement.The partnership, which began with successful hit identification in April 2021, has resulted in joint patent filings and a published research paper in February 2024. Both companies continue to collaborate on additional drug discovery programs using HitGen's DEL platform, which contains over 1.2 trillion small molecules.

6 months ago

#BIOA HitGen Partner BioAge Labs Initiates Phase 1 Clinical Study of BGE-102, a Novel Brain-Penetrant NLRP3 inhibitor

www.stocktitan.net/news/BIOA/hit-gen-partne...

0 0 0 0

BioArctic's founders intend to divest minor part of their shareholding STOCKHOLM, Sept. 3, 2025/ PRNewswire/-- BioArctic AB has been made aware that the company's two founders and main shareholders, Lars Lannfelt and Pär Gellerfors, intend to divest a minor part of their respective shareholding.. This information is information that BioArctic AB is obliged to disclose pursuant to the EU Market Abuse Regulation.

6 months ago

#BIOA BioArctic's founders intend to divest minor part of their shareholding

www.stocktitan.net/news/BIOA/bio-arctic-s-f...

0 0 0 0

First At-Home Weekly Injection Approved: Leqembi IQKLIK Transforms Early Alzheimer's Maintenance Care BioArctic's partner Eisai receives FDA approval for Leqembi IQKLIK autoinjector, enabling weekly at-home maintenance dosing for early Alzheimer's disease. Launch set for October 6, 2025.

6 months ago

#BIOA US FDA approves Leqembi® IQKLIK ™ (lecanemab-irmb) subcutaneous injection for maintenance dosing for the treatment of early Alzheimer's disease

www.stocktitan.net/news/BIOA/us-fda-approve...

0 0 0 0

25% Weight Loss: BioAge's New Oral Drug Shows Breakthrough Results Combined with GLP-1s in Pre-Clinical Study BioAge's BGE-102 achieves 15% weight loss alone, 25% with semaglutide in preclinical studies. Brain-penetrant NLRP3 inhibitor targets inflammation. Phase 1 SAD data expected end-2025.

7 months ago

#BIOA BioAge Labs Announces First Participant Dosed in Phase 1 Clinical Trial of BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor

www.stocktitan.net/news/BIOA/bio-age-labs-a...

0 0 0 0

Sales of Leqembi® totaled 23.1 billion yen in the second quarter 2025 BioArctic AB (Nasdaq Stockholm: BIOA B) reported that its partner Eisai achieved Leqembi® sales of JPY 23.1 billion in Q2 2025. This generated royalty revenue of SEK 162.5 million for BioArctic, representing a 280% increase compared to Q2 2024.The quarter's sales included a one-time stockpiling effect of JPY 5.3 billion in the Chinese market due to tariff risks. Excluding this effect, global sales were JPY 17.8 billion, corresponding to royalty revenue of approximately SEK 125 million.

7 months ago

#BIOA #B Sales of Leqembi® totaled 23.1 billion yen in the second quarter 2025

www.stocktitan.net/news/BIOA/sales-of-leqem...

0 0 0 0

BioArtic: Latest data presented at AAIC 2025 reinforces lecanemab's clinical effect with consistent safety profile BioArctic AB (NASDAQ Stockholm: BIOA B) and partner Eisai presented compelling new data for lecanemab (Leqembi®) at AAIC 2025, showcasing significant treatment benefits over four years. The data demonstrated that lecanemab slows disease progression by approximately one year compared to no treatment over a four-year period.Key findings include: 69% of early-stage patients showed improvement or no decline after four years of treatment, an 84% stability or improvement rate in real-world studies, and promising results for a new subcutaneous administration option. The safety profile remained consistent with previous studies, with decreased ARIA rates after initial 12 months.The real-world study revealed high retention rates of 87%, with 20% of long-term patients improving from mild Alzheimer's to MCI. The new subcutaneous autoinjector showed comparable efficacy to IV administration while offering more convenient at-home treatment options.

7 months ago

#BIOA #B BioArtic: Latest data presented at AAIC 2025 reinforces lecanemab's clinical effect with consistent safety profile

www.stocktitan.net/news/BIOA/bio-artic-late...

0 0 0 0

Major Alzheimer's Breakthrough: Lecanemab Shows 4-Year Efficacy Data, New Dosing Option at AAIC 2025 Latest Lecanemab long-term efficacy data plus new subcutaneous dosing option to be presented at Alzheimer's conference. Get comprehensive trial insights.

7 months ago

#BIOA #B Lecanemab four-year efficacy and safety data to be presented at AAIC 2025

www.stocktitan.net/news/BIOA/lecanemab-four...

0 0 0 0

Alzheimer's Treatment Breakthrough: BioArctic Founder Awarded Major Prize for Lecanemab Development Groundbreaking Alzheimer's researcher honored with 2025 Piepenbrock-DZNE Prize for revolutionary lecanemab treatment development. Learn about this milestone achievement.

8 months ago

#BIOA #B BioArctic: Professor Lars Lannfelt to receive the 2025 Hartwig Piepenbrock-DZNE Prize

www.stocktitan.net/news/BIOA/bio-arctic-pro...

0 0 0 0

BioAge Labs Expands Drug Discovery Platform with Data from Leading European Biobank BioAge Labs (NASDAQ: BIOA) has announced a major expansion of its drug discovery platform through a collaboration with Norwegian diagnostics company Age Labs AS to analyze samples from the HUNT Biobank. The company will profile over 17,000 samples from 6,000+ participants, generating millions of molecular measurements to enhance their proprietary human aging data platform. The analysis will focus on participants who developed cardiometabolic disease (>50%) and cognitive decline/dementia (>35%), using Standard BioTools' SomaScan assay to quantify thousands of proteins per sample. This initiative will complement BioAge's existing platform that contains over 50 million molecular measurements collected across five decades, with exclusive drug discovery rights to the partnership-generated data.

8 months ago

#BIOA BioAge Labs Expands Drug Discovery Platform with Data from Leading European Biobank

www.stocktitan.net/news/BIOA/bio-age-labs-e...

0 0 0 0

BioArctic to initiate next cohorts in exidavnemab Phase 2a study after positive safety review BioArctic announced positive interim safety results for exidavnemab in its Phase 2a EXIST study, enabling progression to higher dose cohorts. The study evaluates exidavnemab as a potential disease-modifying treatment for Parkinson's disease and Multiple System Atrophy (MSA). The first cohort demonstrated that the lower dose was safe and well-tolerated compared to placebo in Parkinson's patients. Two new cohorts will now evaluate higher doses in both Parkinson's and MSA patients. Exidavnemab, a monoclonal antibody, selectively targets pathological alpha-synuclein aggregates while preserving physiological forms. The drug has received orphan drug designation in the US and a positive opinion for orphan medicinal product designation in the EU for MSA treatment. The EXIST study is randomized, double-blinded, and placebo-controlled, evaluating safety, tolerability, pharmacokinetics, and various biomarkers.

9 months ago

#BIOA #B BioArctic to initiate next cohorts in exidavnemab Phase 2a study after positive safety review

www.stocktitan.net/news/BIOA/bio-arctic-to-...

0 0 0 0

BioAge Expands APJ Agonist Pipeline with Oral Small-Molecule and Long-Acting Biologic Candidates BioAge Labs has expanded its APJ agonist pipeline through two significant developments. First, the company entered an option agreement with JiKang Therapeutics to potentially in-license a novel APJ agonist nanobody that is 10-fold more potent than natural apelin. Second, BioAge filed a patent for new orally active small molecule APJ agonists with picomolar potency. The company's preclinical studies show that APJ agonism can double the weight loss effects of GLP-1 receptor agonists while improving muscle function and body composition. BioAge plans to advance both oral and subcutaneous APJ agonists for obesity treatment, targeting an IND filing in 2026. The JiKang agreement includes upfront payments, research funding, and potential milestone payments, while BioAge's internal small molecule program leverages computational modeling and AI design for drug development.

9 months ago

#BIOA BioAge Expands APJ Agonist Pipeline with Oral Small-Molecule and Long-Acting Biologic Candidates

www.stocktitan.net/news/BIOA/bio-age-expand...

0 0 0 0